Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OCULNYSE:OGNNASDAQ:PTCTNASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOCULOcular Therapeutix$6.36-9.1%$7.42$4.06▼$11.78$1.01B1.491.56 million shs2.89 million shsOGNOrganon & Co.$13.04-9.8%$15.16$13.00▼$23.10$3.37B0.732.57 million shs5.01 million shsPTCTPTC Therapeutics$43.24-7.5%$51.22$24.00▼$58.38$3.41B0.58798,535 shs1.31 million shsZLABZai Lab$31.77-13.4%$32.72$13.48▼$39.77$3.48B1.07778,707 shs1.75 million shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOCULOcular Therapeutix-9.14%-16.09%-11.05%-27.40%-24.73%OGNOrganon & Co.-9.59%-10.20%-9.76%-15.58%-27.22%PTCTPTC Therapeutics-7.47%-20.28%-16.73%-7.09%+49.10%ZLABZai Lab-13.41%-14.80%-11.53%+25.57%+99.81%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOCULOcular Therapeutix3.2301 of 5 stars3.40.00.04.13.21.70.0OGNOrganon & Co.4.6553 of 5 stars3.21.03.33.72.81.73.1PTCTPTC Therapeutics3.7239 of 5 stars4.31.00.04.42.60.80.0ZLABZai Lab1.9753 of 5 stars3.41.00.00.02.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOCULOcular Therapeutix 2.88Moderate Buy$16.38157.47% UpsideOGNOrganon & Co. 2.43Hold$20.8059.57% UpsidePTCTPTC Therapeutics 2.53Moderate Buy$63.7747.48% UpsideZLABZai Lab 2.75Moderate Buy$47.3749.09% UpsideCurrent Analyst Ratings BreakdownLatest OCUL, PTCT, ZLAB, and OGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$78.00 ➝ $75.003/27/2025ZLABZai LabCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/18/2025OCULOcular TherapeutixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$17.003/14/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$72.00 ➝ $78.003/13/2025ZLABZai LabJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$44.00 ➝ $51.003/11/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.003/11/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$41.00 ➝ $55.003/7/2025PTCTPTC TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$67.00 ➝ $70.003/7/2025PTCTPTC TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Perform$55.003/7/2025ZLABZai LabScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$55.003/4/2025OCULOcular TherapeutixJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOCULOcular Therapeutix$63.72M15.87N/AN/A$0.79 per share8.05OGNOrganon & Co.$6.40B0.53$4.18 per share3.12($0.27) per share-48.28PTCTPTC Therapeutics$806.78M4.23$2.08 per share20.80($10.85) per share-3.99ZLABZai Lab$398.99M8.73N/AN/A$8.05 per share3.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOCULOcular Therapeutix-$80.74M-$1.26N/AN/AN/A-283.74%-45.18%-30.87%5/6/2025 (Estimated)OGNOrganon & Co.$864M$3.333.913.490.9013.49%431.62%8.03%5/1/2025 (Estimated)PTCTPTC Therapeutics-$626.60M-$4.73N/AN/AN/A-50.32%N/A-16.44%4/24/2025 (Estimated)ZLABZai Lab-$334.62M-$2.59N/AN/AN/A-76.14%-36.97%-27.10%5/6/2025 (Estimated)Latest OCUL, PTCT, ZLAB, and OGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/1/2025N/AOGNOrganon & Co.$0.92N/AN/AN/A$1.53 billionN/A4/24/2025N/APTCTPTC Therapeutics$0.85N/AN/AN/A$437.16 millionN/A3/3/2025Q4 2024OCULOcular Therapeutix-$0.24-$0.29-$0.05-$0.29$16.89 million$17.08 million2/27/2025Q4 2024ZLABZai Lab-$0.61-$0.80-$0.19-$0.80$110.15 million$109.07 million2/13/2025Q4 2024OGNOrganon & Co.$0.92$0.83-$0.09$0.42$1.57 billion$1.59 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOCULOcular TherapeutixN/AN/AN/AN/AN/AOGNOrganon & Co.$1.128.59%+25.99%33.63%N/APTCTPTC TherapeuticsN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ALatest OCUL, PTCT, ZLAB, and OGN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025OGNOrganon & Co.quarterly$0.287.3%2/24/20252/24/20253/13/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOCULOcular Therapeutix0.1913.0112.94OGNOrganon & Co.17.731.701.21PTCTPTC TherapeuticsN/A2.102.04ZLABZai LabN/A3.012.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOCULOcular Therapeutix59.21%OGNOrganon & Co.77.43%PTCTPTC TherapeuticsN/AZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipOCULOcular Therapeutix3.50%OGNOrganon & Co.1.40%PTCTPTC Therapeutics5.50%ZLABZai Lab13.88%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOCULOcular Therapeutix230159.02 million151.71 millionOptionableOGNOrganon & Co.10,000257.95 million253.93 millionNot OptionablePTCTPTC Therapeutics1,41078.87 million72.88 millionOptionableZLABZai Lab1,950109.63 million94.24 millionOptionableOCUL, PTCT, ZLAB, and OGN HeadlinesRecent News About These CompaniesRaymond James Financial Inc. Purchases Shares of 39,420 Zai Lab Limited (NASDAQ:ZLAB)April 5 at 3:03 AM | marketbeat.comZai Lab (NASDAQ:ZLAB) Trading Down 3.5% - Here's What HappenedApril 4 at 11:45 AM | marketbeat.comFrazor Titus Edmondson III Sells 4,369 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockApril 4 at 5:52 AM | insidertrades.comZai Lab Limited (NASDAQ:ZLAB) Position Lessened by Wellington Management Group LLPApril 4 at 4:34 AM | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Up 2.9% - What's Next?April 3 at 12:10 PM | marketbeat.comClearbridge Investments LLC Boosts Stock Position in Zai Lab Limited (NASDAQ:ZLAB)April 2 at 5:14 AM | marketbeat.comZai Lab (NASDAQ:ZLAB) Hits New 1-Year High - What's Next?March 29, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's What HappenedMarch 28, 2025 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Zai Lab (NASDAQ:ZLAB)March 28, 2025 | marketbeat.comZai Lab Limited Reports Strong Revenue Growth and Reduced Losses in 2024March 27, 2025 | tipranks.comFox Run Management L.L.C. Purchases New Holdings in Zai Lab Limited (NASDAQ:ZLAB)March 27, 2025 | marketbeat.comZai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual MeetingMarch 26, 2025 | finance.yahoo.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - Time to Sell?March 22, 2025 | marketbeat.comZai Lab Limited (NASDAQ:ZLAB) Shares Purchased by DCF Advisers LLCMarch 22, 2025 | marketbeat.comZai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) GrowthMarch 21, 2025 | seekingalpha.comZai Lab Limited (NASDAQ:ZLAB) Insider Rafael Amado Sells 3,000 SharesMarch 20, 2025 | marketbeat.comZai Lab: Still Attractive Despite Higher Costs And Added Trade War RisksMarch 20, 2025 | seekingalpha.comRafael Amado Sells 3,000 Shares of Zai Lab Limited (NASDAQ:ZLAB) StockMarch 20, 2025 | insidertrades.comPrivium Fund Management B.V. Has $4.85 Million Position in Zai Lab Limited (NASDAQ:ZLAB)March 20, 2025 | marketbeat.comZurcher Kantonalbank Zurich Cantonalbank Invests $1.67 Million in Zai Lab Limited (NASDAQ:ZLAB)March 18, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Sets New 1-Year High After Analyst UpgradeMarch 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOCUL, PTCT, ZLAB, and OGN Company DescriptionsOcular Therapeutix NASDAQ:OCUL$6.36 -0.64 (-9.14%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$6.60 +0.25 (+3.85%) As of 04/4/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Organon & Co. NYSE:OGN$13.04 -1.42 (-9.79%) Closing price 04/4/2025 03:59 PM EasternExtended Trading$13.04 +0.00 (+0.04%) As of 04/4/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.PTC Therapeutics NASDAQ:PTCT$43.24 -3.49 (-7.47%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$43.21 -0.03 (-0.07%) As of 04/4/2025 05:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Zai Lab NASDAQ:ZLAB$31.77 -4.92 (-13.41%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$31.75 -0.02 (-0.06%) As of 04/4/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Arm Holdings Aims for 50% Data Center Market Share Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
